Joseph A M J L Janssen

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi request reprint Igf-I and longevity
    J A M J L Janssen
    Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    Horm Res 62:104-9. 2004
  2. pmc Igf-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome
    Michael P Brugts
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Diabetes 59:505-8. 2010
  3. pmc Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly
    A J Varewijck
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Diabetologia 55:1186-94. 2012
  4. ncbi request reprint There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients
    J A M J L Janssen
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Endocrinol Invest 27:659-64. 2004
  5. ncbi request reprint [Still no indications that the treatment of growth hormone deficient adults with growth hormones is unsafe]
    J A M J L Janssen
    Erasmus Medisch Centrum, afd Inwendige Geneeskunde, sectie Endocrinologie, Dr Molewaterplein 40, 3015 GD Rotterdam
    Ned Tijdschr Geneeskd 148:1486-9. 2004
  6. ncbi request reprint Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a
    J A M J L Janssen
    Department of Internal Medicine, Room D 436, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:4391-6. 2004
  7. doi request reprint Advantages and disadvantages of GH/IGF-I combination treatment
    J A M J L Janssen
    Department of Internal Medicine, Erasmus MC, Room D425, Rotterdam, The Netherlands
    Rev Endocr Metab Disord 10:157-62. 2009
  8. ncbi request reprint Is there a role of ghrelin in preventing catabolism?
    J A M J L Janssen
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 27:400-3. 2004
  9. doi request reprint Insulin-like growth factor I: pros and cons of a bioassay
    J A M J L Janssen
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Horm Res Paediatr 76:106-10. 2011
  10. ncbi request reprint Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity
    J A M J L Janssen
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 26:588-94. 2003

Collaborators

Detail Information

Publications33

  1. ncbi request reprint Igf-I and longevity
    J A M J L Janssen
    Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
    Horm Res 62:104-9. 2004
    ..For each individual there is probably a specific optimal 'setpoint' for the insulin/growth hormone/IGF-I axis which co-determines survival...
  2. pmc Igf-I bioactivity in an elderly population: relation to insulin sensitivity, insulin levels, and the metabolic syndrome
    Michael P Brugts
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Diabetes 59:505-8. 2010
    ..The purpose of our study was to investigate whether IGF-I bioactivity was related to insulin sensitivity and the metabolic syndrome...
  3. pmc Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly
    A J Varewijck
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Diabetologia 55:1186-94. 2012
    ....
  4. ncbi request reprint There are no acute cardiac effects of a single iv dose of human ghrelin in severe growth hormone deficient patients
    J A M J L Janssen
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Endocrinol Invest 27:659-64. 2004
    ..This suggests that GH-independent effects of ghrelin play no important role in the acute regulation of cardiac function in man...
  5. ncbi request reprint [Still no indications that the treatment of growth hormone deficient adults with growth hormones is unsafe]
    J A M J L Janssen
    Erasmus Medisch Centrum, afd Inwendige Geneeskunde, sectie Endocrinologie, Dr Molewaterplein 40, 3015 GD Rotterdam
    Ned Tijdschr Geneeskd 148:1486-9. 2004
    ..Whether growth-hormone therapy in adult patients with GHD will prove safe in the long term remains to be established...
  6. ncbi request reprint Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a
    J A M J L Janssen
    Department of Internal Medicine, Room D 436, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:4391-6. 2004
    ..In addition, our results indicate that the endocrine IGF-I system is not directly involved in the growth of the early stages of prostate cancer...
  7. doi request reprint Advantages and disadvantages of GH/IGF-I combination treatment
    J A M J L Janssen
    Department of Internal Medicine, Erasmus MC, Room D425, Rotterdam, The Netherlands
    Rev Endocr Metab Disord 10:157-62. 2009
    ..However, determination of whether co-administration of GH and IGF-I indeed is superior to either agent alone awaits further study...
  8. ncbi request reprint Is there a role of ghrelin in preventing catabolism?
    J A M J L Janssen
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 27:400-3. 2004
    ..In conclusion, the anabolic effects of ghrelin in man have still to be demonstrated...
  9. doi request reprint Insulin-like growth factor I: pros and cons of a bioassay
    J A M J L Janssen
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Horm Res Paediatr 76:106-10. 2011
    ..In addition, the IGF-I KIRA seems superior to IGF-I immunoassays for monitoring acute effects of therapeutic interventions...
  10. ncbi request reprint Circulating free insulin-like growth-factor-I (IGF-I) levels should also be measured to estimate the IGF-I bioactivity
    J A M J L Janssen
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Endocrinol Invest 26:588-94. 2003
    ..Therefore, when evaluating the IGF-I bioactivity in health and disease, we recommend measuring also circulating free IGF-I...
  11. ncbi request reprint Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
    J Feenstra
    Department of Internal Medicine, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, Netherlands
    Lancet 365:1644-6. 2005
    ..This combined treatment is effective, might increase compliance, and could greatly reduce the costs of medical treatment for acromegaly in some patients...
  12. doi request reprint Circulating insulin-like growth factors may contribute substantially to insulin receptor isoform A and insulin receptor isoform B signalling
    Aimee J Varewijck
    Division of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Mol Cell Endocrinol 365:17-24. 2013
    ..The aim of this study was to determine total serum insulin-like activity mediated via the insulin receptor isoform A (IR-A) and isoform B (IR-B) by using kinase receptor activation (KIRA) assays specific for the IR-A and IR-B...
  13. doi request reprint Normal values of circulating insulin-like growth factor-I bioactivity in the healthy population: comparison with five widely used IGF-I immunoassays
    Michael P Brugts
    Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 50, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:2539-45. 2008
    ..Recently an IGF-I-specific kinase receptor activation assay (KIRA) has been developed as an alternative method. However, no normative values have been established for the IGF-I KIRA...
  14. doi request reprint IGF-I bioactivity might reflect different aspects of quality of life than total IGF-I in GH-deficient patients during GH treatment
    Aimee J Varewijck
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 98:761-8. 2013
    ..No relationship has been found between improvement in quality of life (QOL) and total IGF-I during GH therapy...
  15. doi request reprint Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
    S J C M M Neggers
    Department of Medicine, Erasmus University, Erasmus MC, Rotterdam, The Netherlands
    Eur J Endocrinol 160:529-33. 2009
    ..We previously reported on the efficacy, safety, and quality of life (QoL) of long-acting somatostatin analogs (SSA) and (twice) weekly pegvisomant (PEG-V) in acromegaly and improvement after the addition of PEG-V to long-acting SSA...
  16. ncbi request reprint Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels
    R A Feelders
    Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 90:6480-9. 2005
    ..It is not exactly known when patients with acromegaly should be evaluated for cure after transsphenoidal adenomectomy (TA)...
  17. doi request reprint Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant
    S J C M M Neggers
    Department of Internal Medicine, Erasmus University Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:3853-9. 2008
    ....
  18. ncbi request reprint Administration of acylated ghrelin reduces insulin sensitivity, whereas the combination of acylated plus unacylated ghrelin strongly improves insulin sensitivity
    C Gauna
    Department of Medicine, Erasmus Medical Center, 3015 GE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 89:5035-42. 2004
    ....
  19. doi request reprint Low circulating insulin-like growth factor I bioactivity in elderly men is associated with increased mortality
    M P Brugts
    Department of Internal Medicine, Erasmus Medical Center, Dr Molewaterplein 50, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 93:2515-22. 2008
    ..The IGF-I kinase receptor activation assay is a novel method for measuring IGF-I bioactivity in human serum. We speculated that determination of circulating IGF-I bioactivity is more informative than levels of immunoreactive IGF-I...
  20. doi request reprint Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy
    Aimee J Varewijck
    Division of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    J Clin Endocrinol Metab 98:769-76. 2013
    ..In addition to the TSH receptor, the IGF-I receptor (IGF-IR) has been proposed to be a second autoantigen that plays a role in the pathogenesis of GO...
  21. pmc Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling
    Aimee J Varewijck
    Division of Endocrinology, Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Diabetes 62:2539-44. 2013
    ..These data suggest that M1 rather than GLA mediates GLA effects and that compared with NPH insulin, GLA does not increase IGF-IR signaling during long-term insulin therapy in type 2 diabetes. ..
  22. doi request reprint Insulin and its analogues and their affinities for the IGF1 receptor
    Aimee J Varewijck
    Division of Endocrinology, Department of Internal Medicine, Erasmus Medical Center, CE Rotterdam, The Netherlands
    Endocr Relat Cancer 19:F63-75. 2012
    ..More detailed information is required to elucidate the exact mechanisms as to how insulin analogues may activate the IR and IGF1R and how this activation may be linked to mitogenesis...
  23. ncbi request reprint An insulin-like growth factor-I gene polymorphism modifies the risk of microalbuminuria in subjects with an abnormal glucose tolerance
    I Rietveld
    Department of Internal Medicine, Rotterdam, The Netherlands
    Eur J Endocrinol 154:715-21. 2006
    ..Microalbuminuria (MA) is related to cardiovascular disease both in diabetic patients and non-diabetic subjects...
  24. pmc High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study
    Ling Oei
    Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    Diabetes Care 36:1619-28. 2013
    ..Individuals with type 2 diabetes have increased fracture risk despite higher bone mineral density (BMD). Our aim was to examine the influence of glucose control on skeletal complications...
  25. doi request reprint Bioactive rather than total IGF-I is involved in acute responses to nutritional interventions in CAPD patients
    Michael P Brugts
    Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
    Nephrol Dial Transplant 25:940-6. 2010
    ..Aim of the study. The aim of the study was to investigate in CAPD patients whether circulating insulin-like growth factor-I (IGF-I) bioactivity may offer a more sensitive index to acute nutritional interventions than total IGF-I...
  26. ncbi request reprint The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?
    J A M J L Janssen
    Department of Internal Medicine, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Eur J Endocrinol 146:467-77. 2002
    ..Clinical trials are necessary to prove that long-term IGF-I treatment, preferably in the form of a better-tolerated IGF-I/IGF-binding protein-3 complex, improves the overall cardiovascular risk in type 2 diabetes...
  27. ncbi request reprint A polymorphic CA repeat in the IGF-I gene is associated with gender-specific differences in body height, but has no effect on the secular trend in body height
    I Rietveld
    Department of Internal Medicine, Erasmus MC Rotterdam, The Netherlands
    Clin Endocrinol (Oxf) 61:195-203. 2004
    ..A polymorphism near the promoter region of the IGF-I gene has been associated with serum IGF-I levels, age-related decline of serum IGF-I levels, body height, birth weight and intima media thickness in hypertensive subjects...
  28. doi request reprint IGF-I bioactivity better reflects growth hormone deficiency than total IGF-I
    A J Varewijck
    Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, 3015 CE Rotterdam, The Netherlands
    J Clin Endocrinol Metab 96:2248-54. 2011
    ..Recently a kinase receptor activation assay was developed to determine IGF-I bioactivity in human serum. The principle of this assay is based on quantification of IGF-I receptor activation after stimulation with serum in vitro...
  29. ncbi request reprint IGF-1 CA repeat variant and breast cancer risk in postmenopausal women
    A M González-Zuloeta Ladd
    Epidemiology and Biostatistics Department, Erasmus MC, Rotterdam, The Netherlands
    Eur J Cancer 43:1718-22. 2007
    ..26 (95% CI=0.95-1.82) for IGF-I CA(19) non-carriers versus CA(19) homozygous carriers. According to these results, the IGF-I CA(19) promoter polymorphism is not likely to predict the risk of breast cancer...
  30. ncbi request reprint Acute stress response in children with meningococcal sepsis: important differences in the growth hormone/insulin-like growth factor I axis between nonsurvivors and survivors
    F de Groof
    Department of Pediatrics, Division of Pediatric Intensive Care, Sophia Children s Hospital, Erasmus University Medical Center, 3000 CB Rotterdam, The Netherlands
    J Clin Endocrinol Metab 87:3118-24. 2002
    ..These values were different from those for the survivors. Based on these findings and literature data a hypothetical model was constructed summarizing our current knowledge and understanding of the various mechanisms...
  31. ncbi request reprint [Hepatocellular carcinoma complicated by non-islet cell tumor hypoglycemia]
    P van Wijngaarden
    Academisch Ziekenhuis Rotterdam Dijkzigt, Postbus 2040, 3000 CA Rotterdam
    Ned Tijdschr Geneeskd 146:859-62. 2002
    ..Therefore, growth hormone was added to the treatment which resulted in a complete disappearance of the hypoglycaemias. The patient died within 6 months of the diagnosis having been established...
  32. pmc A promoter polymorphism of the insulin-like growth factor-I gene is associated with left ventricular hypertrophy
    G S Bleumink
    Heart 91:239-40. 2005
  33. ncbi request reprint Polymorphism in the promoter region of the insulin-like growth factor I gene is related to carotid intima-media thickness and aortic pulse wave velocity in subjects with hypertension
    A F C Schut
    Department of Epidemiology, Erasmus Medical Center Rotterdam, Netherlands
    Stroke 34:1623-7. 2003
    ..We examined the role of this polymorphism in relation to blood pressure and 2 early markers of atherosclerosis: carotid intima-media thickness (IMT) and aortic pulse wave velocity (PWV)...